SUBSCRIBE

Breaking News on Contract Research, Manufacturing & Clinical Trials

Headlines > Clinical Development

News in brief

US CRO contracted by FDA to answer generics safety questions

26-Sep-2012

CRO Vince & Associated Clinical Research (VACR) has won a $5m grant to conduct bioequivalence studies for the US FDA.

Under the contract, Kansas-based VACR will compare generic drugs with innovator products with the initial focus being on anti-epileptic products.

The contract research organisations (CRO)'s president Brad Vince said that: “With this contract we will seek to investigate the bioequivalence of generic products that have resulted in reports of Adverse Events to the FDA.”

He added that: “We are truly excited to partner with the FDA to help address agency concerns with product substitution issues.”

Related products

Key Industry Events

 

Access all events listing

Our events, Events from partners...